[go: up one dir, main page]

NO20082240L - GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser - Google Patents

GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser

Info

Publication number
NO20082240L
NO20082240L NO20082240A NO20082240A NO20082240L NO 20082240 L NO20082240 L NO 20082240L NO 20082240 A NO20082240 A NO 20082240A NO 20082240 A NO20082240 A NO 20082240A NO 20082240 L NO20082240 L NO 20082240L
Authority
NO
Norway
Prior art keywords
polypeptides
glp
methods
imitators
compositions
Prior art date
Application number
NO20082240A
Other languages
English (en)
Inventor
Thomas C Nesspor
Kristen Picha
Audrey E Baker
Beverly A Moore
Karyn O'neil
Jeffery M Palmer
Sarah Sague
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of NO20082240L publication Critical patent/NO20082240L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Pattedyr GLP-2 etterligningsstoffer, polypeptider og nukleinsyrer blir utgreiet. Fremgangsmåter for å benytte etterligningsstoffene og polypeptidene for å behandle GLP-2 relaterte sykdommer blir også utgreiet.
NO20082240A 2005-10-24 2008-05-15 GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser NO20082240L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72970405P 2005-10-24 2005-10-24
US82416006P 2006-08-31 2006-08-31
US86248706P 2006-10-23 2006-10-23
PCT/US2006/060197 WO2007067828A2 (en) 2005-10-24 2006-10-24 Glp-2 mimetibodies, polypeptides, compositions, methods and uses

Publications (1)

Publication Number Publication Date
NO20082240L true NO20082240L (no) 2008-07-22

Family

ID=38123579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082240A NO20082240L (no) 2005-10-24 2008-05-15 GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser

Country Status (11)

Country Link
US (1) US20070212355A1 (no)
EP (1) EP1948785B1 (no)
JP (1) JP2009514508A (no)
KR (1) KR20080071134A (no)
AU (1) AU2006321743A1 (no)
BR (1) BRPI0617515A2 (no)
CA (1) CA2627444A1 (no)
EA (1) EA200801174A1 (no)
IL (1) IL190781A0 (no)
NO (1) NO20082240L (no)
WO (1) WO2007067828A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143679A2 (en) 2006-06-07 2007-12-13 Qualcomm Incorporated Efficient address methods, computer readable medium and apparatus for wireless communication
EP2076604A4 (en) * 2006-08-31 2009-09-02 Centocor Ortho Biotech Inc GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
US12145993B2 (en) * 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
WO2019040399A1 (en) * 2017-08-22 2019-02-28 Shire-Nps Pharmaceuticals, Inc. GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS
IL274098B2 (en) * 2017-11-06 2024-12-01 Shire Nps Pharmaceuticals Inc Glp-2 analogs and peptibodies for administration before during, or after surgery
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
CA3156985A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
IL315253A (en) * 2022-03-03 2024-10-01 Univ Pennsylvania Viral vectors encoding GLP-2 receptor agonist fusions and their uses in the treatment of short bowel syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
EP1360202B1 (en) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
ES2393733T3 (es) * 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
EP1575499A2 (en) * 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
ES2371072T3 (es) * 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
WO2005063282A1 (en) * 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
EA011583B1 (ru) * 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения
US20060084145A1 (en) * 2004-09-27 2006-04-20 Anderson Glenn M sRAGE mimetibody, compositions, methods and uses

Also Published As

Publication number Publication date
EP1948785B1 (en) 2014-01-15
EP1948785A4 (en) 2009-02-04
JP2009514508A (ja) 2009-04-09
IL190781A0 (en) 2008-11-03
BRPI0617515A2 (pt) 2011-07-26
KR20080071134A (ko) 2008-08-01
WO2007067828A3 (en) 2008-04-10
AU2006321743A1 (en) 2007-06-14
WO2007067828A2 (en) 2007-06-14
WO2007067828A9 (en) 2008-05-29
EA200801174A1 (ru) 2009-02-27
CA2627444A1 (en) 2007-06-14
EP1948785A2 (en) 2008-07-30
US20070212355A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
NO20091064L (no) Antistoffer mot IL-17A
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
SG165353A1 (en) Improved human interferon molecules and their uses
CL2011000206A1 (es) Composicion biocida que comprende ciprodinil y fluazinam; metodo para controlar enfermedades, en plantas utiles o en material de propagacion, causadas por fitopatogenos (div. sol. n°2602-06).
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK2068909T3 (da) Modificerede FGF-21-polypeptider og anvendelse heraf
EA201000146A1 (ru) Связующее майларда на основе гидроксимонокарбоновой кислоты
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
NO20082531L (no) Neuropilinantagonister
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
DE602006014121D1 (de) Sicheres druckverfahren zur verhinderung von produktfälschung
EA200701592A1 (ru) Композиты и способы их получения и использования
BRPI0909566A2 (pt) Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
DK1937448T3 (da) Formaldehydfattigt lignocellulosemateriale og fremgangsmåde til dennes fremstilling
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
ATE501731T1 (de) Melanocortin-rezeptor-bindende mimetibodies, zusammensetzungen, verfahren und verwendungen
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application